Trials / Completed
CompletedNCT02299141
Nintedanib in Molecularly Selected Patients With Advanced Non-Small Cell Lung Cancer
A Pilot Study of Nintedanib in Molecularly Selected Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 20 (actual)
- Sponsor
- Washington University School of Medicine · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
There has been limited benefit with angiogenesis inhibitor drugs in molecularly unselected patients in non-small cell lung cancer (NSCLC). The investigators propose that patients who are molecularly selected for treatment with nintedanib based on the presence of mutations in the following genes: VEGFR1-3, PDGFR-A, PDGFR-B, FGFR1-3, and TP53, will have clinically meaningful benefit in terms of response rate (RR) and progression-free survival (PFS). Furthermore the investigators plan to correlate outcomes with specific mutations and evaluate mechanisms of resistance.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Nintedanib |
Timeline
- Start date
- 2015-05-07
- Primary completion
- 2020-01-09
- Completion
- 2025-04-23
- First posted
- 2014-11-24
- Last updated
- 2025-06-24
- Results posted
- 2021-02-21
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT02299141. Inclusion in this directory is not an endorsement.